Physician profile
Javier Gonzalez
NPI 1669791224
$5,352.01
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $86.89 · 2021: $123 · 2022: $3,792 · 2023: $615 · 2024: $383 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,768.72 | 2022-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $326.95 | 2019-2024 | Trelegy Ellipta |
| Inari Medical, INC. | $182.62 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $118.00 | 2023 | Inspire |
| Amgen INC. | $114.06 | 2023 | Repatha |
| Mannkind Corporation | $108.17 | 2023 | Afrezza |
| Actelion Pharmaceuticals US, INC. | $106.48 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.45 | 2019-2022 | |
| Insmed, INC. | $71.60 | 2022-2024 | Arikayce |
| Lundbeck LLC | $67.68 | 2020-2021 | |
| Impel Pharmaceuticals LLC | $57.17 | 2025 | Trudhesa |
| Amphastar Pharmaceuticals, INC. | $47.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $43.77 | 2022 | |
| Resmed Corp | $37.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.98 | 2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $34.70 | 2024-2025 | |
| Ibsa Pharma INC. | $34.27 | 2023 | Tirosint, Licart |
| Corcept Therapeutics | $29.10 | 2024 | Korlym |
| Ascendis Pharma Endocrinology INC | $23.92 | 2023 | |
| Cardinal Health 414 LLC | $18.22 | 2024 | |
| Roche Diabetes Care, INC. | $16.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.